Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
about
A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulationTherapeutics for Circadian Rhythm Sleep DisordersComparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake DisordersMT1 and MT2 Melatonin Receptors: A Therapeutic PerspectiveEffect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian PhysiologyAdministration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male RatsSleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the ratSleep physiology, abnormal States, and therapeutic interventions.Systems ChronotherapeuticsA phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorderMelatonin agonists and insomnia.Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.Melatonergic drugs in development.Manipulating the sleep-wake cycle and circadian rhythms to improve clinical management of major depression.Neurochemical and neuropharmacological aspects of circadian disruptions: an introduction to asynchronization.Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Circadian and wakefulness-sleep modulation of cognition in humansMelatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular SMelatonin Therapy in Patients with Alzheimer's Disease.Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survivalTherapeutic application of melatonin in mild cognitive impairment.New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.Emerging drugs for insomnia: new frontiers for old and novel targets.Clock-Enhancing Small Molecules and Potential Applications in Chronic Diseases and Aging.Investigational melatonin receptor agonists.Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.Jet lag and psychotic disorders.Tasimelteon for insomnia.Melatonin receptor agonists: new options for insomnia and depression treatment.MAGED1: molecular insights and clinical implications.Pharmacotherapy of insomnia.Drugs for insomnia.Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.Cardiovascular effects of melatonin receptor agonists.Tasimelteon: first global approval.Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
P2860
Q22305782-8E8A1F26-C12F-4363-902B-BFBE2A304BC3Q24600160-533E5DEE-0844-4770-91ED-40528531EB2DQ28074572-03C93D5F-C957-4EB1-8663-AA28CEB641C0Q28083929-BC854B49-B896-4064-B84C-85583216FC48Q28394033-46A5E82A-AE5C-44D9-BB1B-69E41D521A7AQ28395600-E554EE62-BB8D-4760-BBA8-D64E4D23A332Q28572907-827F75E5-1DA1-4297-BAEB-E03D608F0A03Q30465865-195FB7B2-68C0-419B-8CB1-42CC6F78DE89Q33573675-288D873B-9A65-40AE-B984-A39C60A21A13Q33951540-2959B716-0310-4F39-BF4E-4849402C1E01Q34097173-A8503DA1-9F86-4560-80ED-98BB47CDBC93Q34358480-BF9375FA-9DCB-4834-9FC6-C91F39E4BD4DQ34440574-D88FBA4F-8023-452E-9B61-28E6E514A75FQ34632470-F8698B2C-E159-44F0-ACFC-2D1F609CF7C0Q35092159-33078467-6B72-4245-ABF8-491C544D80F2Q35276597-22EB2824-E9BE-4EDB-9E86-ACBF4CF39EAEQ35671396-755D8B56-A004-49A7-AC5D-8559E16771E7Q35895575-650EDC2A-7D62-4644-B989-4E8924AC3375Q36040915-BAB7EA37-1409-4308-8689-54964DA52B74Q36090692-8CE5BEE2-7B7D-4B7A-BA20-7BA36FCCD34FQ36335048-2CE0E2BA-A697-4DF8-8A5B-311ED4CFDF68Q36554668-CB390D08-1875-4F88-A82C-C48052C128A2Q36576496-1C28ABFA-FB10-4AF0-8131-B43AA9FE0CC0Q37235719-87D0F6B4-A2F4-4947-AAA4-F4D0194546EEQ37587178-782F1582-DCD6-466D-AD25-C336B4C85869Q37699510-67F5D780-DD1C-41E3-9D30-6F4F548E6C42Q37735169-9445DF08-506D-4049-9EB4-5B88E77DB319Q37763715-A54F0F7C-4C4C-42A1-9B7F-50CE66D8BE4DQ37848695-283D81F7-4866-4904-BBCE-B9ED09F76E76Q37872781-CF8D462B-28D8-4458-8A58-6AEAEE3BCB01Q37873581-553BA132-1ED0-45D6-A78D-D7589B94F2E5Q37879671-323BAABF-364F-4009-889F-EF9FBBD0FDC5Q38009370-23DAE77F-0EAA-410D-A4F7-4325B09BB22BQ38017272-B2BFA04F-7851-45CB-9A42-D22B74B716D8Q38022179-52DE3D2A-22BC-4F53-AFA1-472E4B5EF670Q38037124-8D4E2FF0-EFD9-4205-B37E-2FC5D4095187Q38194529-D2BA030D-7EAE-48C1-9760-93DBD1C303E5Q38237022-BFAB420F-5156-429F-9DDA-CDEA30170281Q38247486-E284C67C-2BBA-43C4-86A2-D8A738F2F313Q38271225-4FEBC2FF-4D11-42E8-B199-FEA24E3A588C
P2860
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Melatonin agonist tasimelteon ...... controlled multicentre trials.
@ast
Melatonin agonist tasimelteon ...... controlled multicentre trials.
@en
Melatonin agonist tasimelteon
@nl
type
label
Melatonin agonist tasimelteon ...... controlled multicentre trials.
@ast
Melatonin agonist tasimelteon ...... controlled multicentre trials.
@en
Melatonin agonist tasimelteon
@nl
prefLabel
Melatonin agonist tasimelteon ...... controlled multicentre trials.
@ast
Melatonin agonist tasimelteon ...... controlled multicentre trials.
@en
Melatonin agonist tasimelteon
@nl
P2093
P921
P1433
P1476
Melatonin agonist tasimelteon ...... controlled multicentre trials
@en
P2093
Christin Scott
Dennis M Fisher
Elizabeth B Klerman
Mihael H Polymeropoulos
Thomas Roth
P304
P356
10.1016/S0140-6736(08)61812-7
P407
P577
2008-12-04T00:00:00Z